Coherus BioSciences, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Generic Drugs

Other Names/Subsidiaries

  • Coherus Intermediate
  • InteKrin Therapeutics
See more in Biomedtracker

Latest on Coherus BioSciences, Inc.

Scrip

Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US Data

 
• By Dexter Jie Yan

Akeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke

Generics Bulletin

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

 
• By Dave Wallace

Aeon Biopharma, which is working on developing a biosimilar version of Botox (onabotulinumtoxinA) in the US, has looked to rival developer Revance Therapeutics to recruit its new chief executive. Aeon

Generics Bulletin

Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment

 
• By Dave Wallace

It’s official: Coherus BioSciences is finally out of the biosimilars business. The company has marked the end of a long road to transition from being a biosimilars player to an innovative immuno-oncol

Generics Bulletin

Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff

 
• By Dave Wallace

With Coherus BioSciences gearing up to exit the biosimilars space altogether – having late last year struck a deal to divest its Udenyca (pegfilgrastim-cbqv) franchise to Intas in a transaction wort